middle.news
Neurizon Secures $44M to Propel NUZ-001 in Pivotal ALS Trial
9:59am on Tuesday 23rd of December, 2025 AEDT
•
Biotechnology
Read Story
Neurizon Secures $44M to Propel NUZ-001 in Pivotal ALS Trial
9:59am on Tuesday 23rd of December, 2025 AEDT
Key Points
Placement raises ~$7.1 million at $0.08 per share
2-for-5 pro rata entitlement offer targets up to ~$17.1 million
$20 million convertible note facility with Obsidian Global GP, LLC
Funding covers full HEALEY ALS Platform Trial participation and extension phases
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE